Dr. Flaherty on Second-Line Therapy for BRAF-Mutant Melanoma

Source: OncLive, November 2019

Keith T. Flaherty, MD, professor of medicine, Harvard Medical School, director, Henri and Belinda Termeer Center for Targeted Therapy, director of clinical research, Massachusetts General Hospital, discusses treatment beyond frontline therapy for patients with BRAF-mutant relapsed/refractory melanoma.

For patients without a BRAF mutation, physicians only deliberate on immunotherapy options, including monotherapy or combination therapy, says Flaherty. Treatment is more complicated for the BRAF-mutant population because there are more options and clinical trials; however, most of these clinical trials examine treatment-naïve patients, meaning these treatments are not looked at in the second-line setting and beyond, explains Flaherty.